Building a Biotech From Zero (Part 2 of 2): Investor Reality, Liquidity Myths & Founder Dynamics
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Building a Biotech From Zero (Part 2 of 2): Investor Reality, Liquidity Myths & Founder Dynamics
-
Narrated by:
-
By:
About this listen
In Part 2, Ray and David continue their deep dive into the realities of early-stage biotech growth—moving into warrant coverage, investor upside, dilution, and the often-overlooked truth that early equity can be illiquid for years.
David breaks down liquidation waterfalls, down rounds, fiduciary duties, and what happens when a company approaches insolvency.
They close with a candid look at managing founder relationships, avoiding “dead equity,” and keeping the company aligned when the science, money, and people all collide.
- 01:43 Understanding Conversion Discounts
- 02:07 Negotiation Points and Valuation
- 03:11 Enterprise Value and Share Price
- 04:37 Impact on Founders' Equity
- 08:47 Capital Gains Tax Benefits
- 13:47 Liquidity and Exit Strategies
- 19:07 Investor Motivations and Risks
- 34:20 Board and Management Obligations
- 43:11 Ray's Retreat Overview
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.